You are here
Our primary avenues of research focus on the physiological consequences of hormone signaling: from receptors to gene expression to phenotypes. New Receptors: We engineered GPCRs called RASSLs (Receptor Activated Solely by a Synthetic Ligand) to control signaling at the receptor level. RASSLs can be expressed in specific tissues and then activated by synthetic small molecule drugs. Bioinformatics: We developed a public software tool called GenMAPP to analyze gene expression data in the context of known biochemical or signaling pathways. Genome engineering: We are involved in a large-scale collaboration, BayGenomics, to contribute to the functional inactivation of all genes in the mouse genome.